• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Transcarent Experience Store Expansion: More Options for Women's Health

    10/21/25 9:30:00 AM ET
    $PGNY
    Misc Health and Biotechnology Services
    Health Care
    Get the next $PGNY alert in real time by email

    Maven Clinic, Midi Health, and Progyny provide support for menopause, perimenopause, and family building for Transcarent Members

    Easy access through WayFinding™ AI experience is a gamechanger

    Transcarent, the One Place for Health and Care, today announced three additional women's health partners: Maven Clinic, Midi Health, and Progyny, joining existing partners, Carrot and Kindbody, to deliver more choices for employers and health plans who want to make it easier for women to find the care they need.

    This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251021108964/en/

    Transcarent Experience Store expands with additions of Women's Health partners: Maven Clinic, Midi Health, and Progyny

    Transcarent Experience Store expands with additions of Women's Health partners: Maven Clinic, Midi Health, and Progyny

    Women are often the primary healthcare decision makers for their families, and they have unique health needs that change throughout their lives. The Transcarent Experience Store makes it easy for employers and health plans to find and choose the highest-quality solutions for their Members, without having to separately contract with each solution, delivering single sign-on, accessing consolidated reporting, and being able to see measurable outcomes for the entire person. Transcarent Members can use women's health solutions directly from the WayFinding™ experience, the first and only platform using generative AI to improve the experience people have with their care. Transcarent's WayFinding experience makes it easy for women to find and use the services they need. The results speak for themselves — employers using the WayFinding experience show 7.6x more referrals to women's health solutions.

    "Women are the chief health officers of their households, and they deserve world-class support at every stage — from family building to menopause," said Snezana Mahon, Pharm.D., President of Transcarent. "Adding partners like Maven Clinic, Midi Health, and Progyny along with Carrot and Kindbody gives our clients access to every industry leading solution, all in one place. As we mark October as Menopause Awareness Month, we're especially proud to elevate access to expert midlife women's care."

    What's new in the Experience Store

    • Maven Clinic: An end-to-end platform supporting preconception, fertility, pregnancy, parenting, and menopause, with 24/7 access to the largest virtual care network in women's and family health and proven ROI across diverse populations.
    • Midi Health: The leading women's virtual clinic offering expert care for perimenopause, menopause, and other midlife concerns.
    • Progyny: Comprehensive, personalized care across the spectrum from preconception, fertility and family building, to pregnancy, parenting, and menopause. Progyny's network of specialty trained providers and dedicated Progyny Care Advocates support members every step of their journey.

    "Having a baby, raising children, navigating midlife—these are some of life's most meaningful moments and also crucial windows for intervention in the trajectory of someone's lifelong health," said Kate Ryder, CEO and Founder of Maven Clinic. "Together with Transcarent, we're meeting women and families when they need us most with comprehensive, always-on care across every stage of life, while saving costs for their employers."

    "Midlife women have been underserved for far too long," said Joanna Strober, CEO & Co-founder of Midi Health. "By joining the Transcarent Experience Store, we're meeting women where they are with expert menopause and perimenopause care that is personalized, accessible, and grounded in clinical best practices."

    "By providing access to the right care that comes hand-in-hand with personal advocates who support members along the journey, we're empowering women and families to achieve their health goals," said Pete Anevski, CEO, Progyny. "Progyny's commitment to clinical excellence and to innovating how members connect with the care they need is at the heart of our partnership with Transcarent. By combining our comprehensive care model with Transcarent's platform, we're expanding access to the kind of expert support and improved outcomes that can have a truly meaningful impact on both employers and the growing families in their care."

    "We're proud to be a pioneering partner of Transcarent's Experience Store, offering the gold standard for integrated fertility and family building care," said Tammy Sun, Founder and CEO of Carrot. "At Carrot, our global reach and comprehensive approach helps Members navigate through all of these moments – from addressing metabolic health and root causes of infertility, to supporting diverse paths to parenthood, and managing menopause transitions. Together, we're making it easier for employers to provide truly inclusive care to support the entire workforce across the full spectrum of reproductive health."

    "Nearly two years into our partnership, we've seen meaningful traction helping employers and health plans seamlessly connect their Members with the right fertility and menopause care at the right time," said David Stern, CEO of Kindbody. "Together with Transcarent, we're expanding access to an essential healthcare benefit that touches the full spectrum of reproductive care while delivering measurable outcomes and simplifying the way organizations provide family-building support."

    How it works for Members and employers

    The Transcarent Experience Store allows employers and health plans to choose the best solutions for the people they serve, all available on one secure platform. Employers and health plans gain the simplicity of access to multiple partners for their employees and Members in one place, unified eligibility and activation, integrated reporting and analytics, and a consistent experience across conditions and partners.

    Transcarent carefully evaluates partners for clinical quality, security, financial stability, and operational excellence so employers and health plans can move forward with confidence. The Experience Store enables point solution partners to integrate into the Transcarent platform, providing Members with support for diverse needs, including mental health, diabetes, fertility, and musculoskeletal care. By reducing fragmentation, we increase the utilization of point solutions by 10-20%.

    About Transcarent

    Transcarent is the One Place for Health and Care, bringing medical, pharmacy, and point solutions together with the WayFinding™ experience, the first and only generative AI-powered health and care platform for health consumers. Our WayFinding experience, paired with transparent and consumer-driven pharmacy care, 2nd.MD expert medical opinions, and virtual primary care, works seamlessly with comprehensive Care Experiences – Cancer Care, Surgery Care, and Weight Health – to support people with all of their health needs, simple or serious. We also provide seamless access to the leading point solutions through our Experience Store. More than 1,700 employers and health plans rely on us to provide information, guidance, and care, empowering health consumers with more choice, an experience they love, access to higher-quality care, and lower costs for more than 20 million people. For more information, visit www.transcarent.com, and follow us on LinkedIn.

    About Maven Clinic

    Maven is the world's largest virtual clinic for women and families on a mission to make healthcare work for all of us. Maven's award-winning digital programs provide clinical, emotional, and financial support all in one platform, spanning fertility & family building, maternity & newborn care, parenting & pediatrics, and menopause & midlife. More than 2,000 employers and health plans trust Maven's end-to-end platform to improve clinical outcomes, reduce healthcare costs, and provide equity in benefits programs. Recognized for innovation and industry leadership, Maven has been named to the Time 100 Most Influential Companies, CNBC Disruptor 50, Fast Company Most Innovative Companies, and FORTUNE Best Places to Work. Founded in 2014 by CEO Kate Ryder, Maven has raised more than $425 million in funding from top healthcare and technology investors including General Catalyst, Sequoia, Dragoneer Investment Group, Oak HC/FT, StepStone Group, Icon Ventures, and Lux Capital. To learn more about Maven, visit us at mavenclinic.com.

    About Midi Health

    Midi Health is the fastest growing virtual care clinic focused on women navigating midlife hormonal change and beyond. With treatment protocols created by world-class medical experts in perimenopause and menopause, delivered by clinicians trained in women's midlife health, Midi Health provides patients with personalized care plans that include hormonal and non-hormonal medications, supplements, lifestyle coaching and more. All services are covered by insurance, and conveniently accessible through telehealth visits and 24/7 messaging. To learn more, visit www.joinmidi.com.

    About Progyny

    Progyny (NASDAQ:PGNY) is a global leader in women's health and family building solutions, trusted by the nation's leading employers, health plans and benefit purchasers. We envision a world where everyone can realize their dreams of family and ideal health. Our outcomes prove that comprehensive, inclusive, and intentionally designed solutions simultaneously benefit employers, patients, and physicians.

    Our benefits solution empowers patients with concierge support, coaching, education, and digital tools; provides access to a premier network of fertility and women's health specialists who use the latest science and technologies; drives optimal clinical outcomes; and reduces healthcare costs.

    Headquartered in New York City, Progyny has been recognized for its leadership and growth as a TIME100 Most Influential Company, CNBC Disruptor 50, Modern Healthcare's Best Places to Work in Healthcare, Forbes' Best Employers, Financial Times Fastest Growing Companies, Inc. 5000, Inc. Power Partners, and Crain's Fast 50 for NYC. For more information, visit www.progyny.com.

    About Carrot

    Carrot is a global, comprehensive fertility and family care platform, supporting members and their families through life's most memorable moments. Trusted by many of the world's leading multinational employers, health plans, and health systems, Carrot delivers exceptional clinical outcomes, industry-leading cost savings, and a seamless member experience. Its award-winning products serve all populations–from preconception care through pregnancy, IVF, male-factor infertility, adoption, gestational carrier care, and menopause. With localized support in more than 170 countries and 25 languages, Carrot's clinically driven, human-centered approach ensures personalized, high-quality care for everyone, everywhere. Learn more at get-carrot.com.

    About Kindbody

    Kindbody is the leading U.S. fertility clinic network and global family-building benefits provider for employers on a mission to make fertility care more affordable and accessible for all. Kindbody serves patients at 27 state-of-the-art signature clinics and IVF labs, 400+ partner clinics, and in 113 countries around the world. Trusted by more than 135 employers, Kindbody's physician-led model covers the full-spectrum of reproductive healthcare including fertility assessments, fertility preservation, genetic testing, IVF, donor and surrogacy services, adoption, postpartum care, and menopause support. Kindbody is the only fertility benefits provider that serves patients directly, delivering a seamless, integrated experience with superior health outcomes at lower cost. Recognized for technology innovation and industry leadership, Kindbody has been named to CNBC Disruptor 50, Fast Company's Brands that Matter, Forbes Best Startup Employers, Inc.'s Best In Business list of most admired companies, as well as Deloitte Technology Fast 500™, which recognizes the fastest growing and most innovative technology companies in North America. Founded in 2018, Kindbody has raised more than $315 million in debt and equity funding from leading investors including Perceptive Advisors, JP Morgan Chase's Morgan Health, GV, RRE Ventures, Claritas Health Ventures, Rock Springs Capital, Distributed Ventures, Whatif Ventures and TQ Ventures. Visit www.kindbody.com and follow us on Instagram and LinkedIn.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20251021108964/en/

    Media Contact

    Leslie Krigstein

    VP, Communications & Government Affairs

    Transcarent

    [email protected]

    Get the next $PGNY alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PGNY

    DatePrice TargetRatingAnalyst
    7/8/2025$28.00Market Perform → Outperform
    Leerink Partners
    12/2/2024$17.00Overweight → Neutral
    Analyst
    11/13/2024$26.00 → $19.00Buy → Hold
    Truist
    9/19/2024Mkt Outperform → Mkt Perform
    JMP Securities
    8/7/2024$37.00 → $24.00Buy → Hold
    Canaccord Genuity
    8/7/2024$31.00 → $25.00Outperform → Market Perform
    Leerink Partners
    8/7/2024Buy → Neutral
    BTIG Research
    7/16/2024$36.00Mkt Outperform
    JMP Securities
    More analyst ratings

    $PGNY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Executive Chairman Schlanger David J covered exercise/tax liability with 1,893 shares, decreasing direct ownership by 0.85% to 220,419 units (SEC Form 4)

    4 - Progyny, Inc. (0001551306) (Issuer)

    10/2/25 4:26:50 PM ET
    $PGNY
    Misc Health and Biotechnology Services
    Health Care

    CHIEF EXECUTIVE OFFICER Anevski Peter covered exercise/tax liability with 7,977 shares, decreasing direct ownership by 1% to 539,564 units (SEC Form 4)

    4 - Progyny, Inc. (0001551306) (Issuer)

    10/2/25 4:24:46 PM ET
    $PGNY
    Misc Health and Biotechnology Services
    Health Care

    EVP, GC Swartz Allison sold $14,094 worth of shares (599 units at $23.53) and covered exercise/tax liability with 339 shares, decreasing direct ownership by 1% to 77,407 units (SEC Form 4)

    4 - Progyny, Inc. (0001551306) (Issuer)

    9/5/25 4:39:46 PM ET
    $PGNY
    Misc Health and Biotechnology Services
    Health Care

    $PGNY
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Transcarent Experience Store Expansion: More Options for Women's Health

    Maven Clinic, Midi Health, and Progyny provide support for menopause, perimenopause, and family building for Transcarent Members Easy access through WayFinding™ AI experience is a gamechanger Transcarent, the One Place for Health and Care, today announced three additional women's health partners: Maven Clinic, Midi Health, and Progyny, joining existing partners, Carrot and Kindbody, to deliver more choices for employers and health plans who want to make it easier for women to find the care they need. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251021108964/en/Transcarent Experience Store expands with additions of Women's

    10/21/25 9:30:00 AM ET
    $PGNY
    Misc Health and Biotechnology Services
    Health Care

    Progyny CEO Named World Economic Forum Champion for Women's Health

    NEW YORK, Oct. 07, 2025 (GLOBE NEWSWIRE) -- Progyny, Inc. (NASDAQ:PGNY), a global leader in women's health and family building solutions, today announced that CEO Pete Anevski has been honored with the recognition as a Champion for Women's Health by the World Economic Forum (the Forum) and the Global Alliance for Women's Health (GAWH). The community of Champions is a distinguished group of global leaders who are playing a critical role in driving advocacy efforts, shaping policies, fostering innovation, and unlocking investments to advance women's health. The exclusive Champions community spans diverse sectors, industries, and geographies, and includes figures such as: Helen Clark, former

    10/7/25 9:30:50 AM ET
    $PGNY
    Misc Health and Biotechnology Services
    Health Care

    Progyny, Inc. Announces Second Quarter 2025 Results

    Reports Record Revenue of $332.9 Million, Reflecting 9.5% GrowthGenerates $55.5 Million in Quarterly Operating Cash Flow and Record $105.3 Million over the First Half of 2025 Raises Full Year Guidance to Reflect Continued Increase in Pacing of Member Engagement NEW YORK, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Progyny, Inc. (NASDAQ:PGNY) ("Progyny" or the "Company"), a global leader in women's health and family building solutions, today announced its financial results for the three-month period ended June 30, 2025 ("the second quarter of 2025") as compared to the three-month period ended June 30, 2024 ("the second quarter of 2024" or "the prior year period"). "The strong second quarter results

    8/7/25 4:02:43 PM ET
    $PGNY
    Misc Health and Biotechnology Services
    Health Care

    $PGNY
    SEC Filings

    View All

    SEC Form 144 filed by Progyny Inc.

    144 - Progyny, Inc. (0001551306) (Subject)

    8/11/25 1:58:09 PM ET
    $PGNY
    Misc Health and Biotechnology Services
    Health Care

    SEC Form 10-Q filed by Progyny Inc.

    10-Q - Progyny, Inc. (0001551306) (Filer)

    8/8/25 9:04:45 AM ET
    $PGNY
    Misc Health and Biotechnology Services
    Health Care

    Progyny Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Progyny, Inc. (0001551306) (Filer)

    8/7/25 4:07:11 PM ET
    $PGNY
    Misc Health and Biotechnology Services
    Health Care

    $PGNY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Progyny upgraded by Leerink Partners with a new price target

    Leerink Partners upgraded Progyny from Market Perform to Outperform and set a new price target of $28.00

    7/8/25 11:08:47 AM ET
    $PGNY
    Misc Health and Biotechnology Services
    Health Care

    Progyny downgraded by Analyst with a new price target

    Analyst downgraded Progyny from Overweight to Neutral and set a new price target of $17.00

    12/2/24 10:07:08 AM ET
    $PGNY
    Misc Health and Biotechnology Services
    Health Care

    Progyny downgraded by Truist with a new price target

    Truist downgraded Progyny from Buy to Hold and set a new price target of $19.00 from $26.00 previously

    11/13/24 8:20:07 AM ET
    $PGNY
    Misc Health and Biotechnology Services
    Health Care

    $PGNY
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Executive Chairman Schlanger David J bought $2,202,330 worth of shares (150,000 units at $14.68), increasing direct ownership by 192% to 228,269 units (SEC Form 4)

    4 - Progyny, Inc. (0001551306) (Issuer)

    12/26/24 5:35:03 PM ET
    $PGNY
    Misc Health and Biotechnology Services
    Health Care

    CHIEF EXECUTIVE OFFICER Anevski Peter bought $3,034,084 worth of shares (209,500 units at $14.48), increasing direct ownership by 90% to 441,463 units (SEC Form 4)

    4 - Progyny, Inc. (0001551306) (Issuer)

    12/26/24 5:31:32 PM ET
    $PGNY
    Misc Health and Biotechnology Services
    Health Care

    $PGNY
    Leadership Updates

    Live Leadership Updates

    View All

    Progyny CEO Named World Economic Forum Champion for Women's Health

    NEW YORK, Oct. 07, 2025 (GLOBE NEWSWIRE) -- Progyny, Inc. (NASDAQ:PGNY), a global leader in women's health and family building solutions, today announced that CEO Pete Anevski has been honored with the recognition as a Champion for Women's Health by the World Economic Forum (the Forum) and the Global Alliance for Women's Health (GAWH). The community of Champions is a distinguished group of global leaders who are playing a critical role in driving advocacy efforts, shaping policies, fostering innovation, and unlocking investments to advance women's health. The exclusive Champions community spans diverse sectors, industries, and geographies, and includes figures such as: Helen Clark, former

    10/7/25 9:30:50 AM ET
    $PGNY
    Misc Health and Biotechnology Services
    Health Care

    Progyny Appoints Two Renowned Women's Health Experts to Medical Advisory Board

    NEW YORK, May 14, 2025 (GLOBE NEWSWIRE) -- Progyny, Inc. (NASDAQ:PGNY), a global leader in women's health and family building solutions, today announced the appointment of Morehouse School of Medicine's Regional Dean for Seattle and Puget Sound's Dr. Gloria Richard-Davis – a double-board certified physician in Obstetrics and Gynecology and Reproductive Endocrinology and Infertility, a fellow of the American College of Obstetricians & Gynecologists (FACOG), and a Menopause Society Certified Practitioner (MSCP) – and Columbia University's Dr. Whitney Booker – a double-board certified physician in Obstetrics and Gynecology and Maternal-Fetal Medicine – to its Medical Advisory Board. "As Pr

    5/14/25 9:05:48 AM ET
    $PGNY
    Misc Health and Biotechnology Services
    Health Care

    Progyny Names Healthcare Veterans Melissa Cummings as Chief Operating Officer and Geoffrey Clapp as Chief Product Officer

    NEW YORK, April 17, 2025 (GLOBE NEWSWIRE) -- Progyny (NASDAQ:PGNY), a global leader in women's health and family building, today announced the appointments of Melissa Cummings as the company's first Chief Operating Officer (COO) and Geoffrey Clapp as its first Chief Product Officer (CPO). The additions to the executive leadership team will extend Progyny's ability to further drive operational excellence, advance innovation in product design and member experience, and continue to address care gaps and unmet needs across the spectrum of family building and women's health – from preconception to fertility and menopause. "Progyny has established itself at the forefront of building and del

    4/17/25 9:36:59 AM ET
    $PGNY
    Misc Health and Biotechnology Services
    Health Care

    $PGNY
    Financials

    Live finance-specific insights

    View All

    Progyny, Inc. Announces Second Quarter 2025 Results

    Reports Record Revenue of $332.9 Million, Reflecting 9.5% GrowthGenerates $55.5 Million in Quarterly Operating Cash Flow and Record $105.3 Million over the First Half of 2025 Raises Full Year Guidance to Reflect Continued Increase in Pacing of Member Engagement NEW YORK, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Progyny, Inc. (NASDAQ:PGNY) ("Progyny" or the "Company"), a global leader in women's health and family building solutions, today announced its financial results for the three-month period ended June 30, 2025 ("the second quarter of 2025") as compared to the three-month period ended June 30, 2024 ("the second quarter of 2024" or "the prior year period"). "The strong second quarter results

    8/7/25 4:02:43 PM ET
    $PGNY
    Misc Health and Biotechnology Services
    Health Care

    Progyny, Inc. Provides Business Update and Announces Details for Its Second Quarter 2025 Results Report

    Operational and Financial Flexibility Enhanced Through New Credit FacilitySecond Quarter Results Anticipated to be Slightly Above Previously Provided Financial Guidance NEW YORK, July 08, 2025 (GLOBE NEWSWIRE) -- Progyny, Inc. (NASDAQ:PGNY) ("Progyny" or the "Company"), a global leader in women's health and family building solutions, today announced that it has entered into a revolving credit facility (the "revolver" or the "facility") which makes available to the Company up to $200 million in aggregate revolving credit commitments, which the Company can utilize for revolving credit borrowings, subject to customary borrowing conditions, until maturity on July 1, 2030. The facility is expe

    7/8/25 8:09:00 AM ET
    $PGNY
    Misc Health and Biotechnology Services
    Health Care

    Progyny, Inc. Announces First Quarter 2025 Results

    Reports Record Revenue of $324.0 Million, Reflecting 16.5% GrowthRaises Full Year Guidance Due to Strong Start to the YearEarly Selling Season Activity Reflects Ongoing Demand in Women's Health and Family Building Solutions NEW YORK, May 08, 2025 (GLOBE NEWSWIRE) -- Progyny, Inc. (NASDAQ:PGNY) ("Progyny" or the "Company"), a global leader in women's health and family building solutions, today announced its financial results for the three-month period ended March 31, 2025 ("the first quarter of 2025") as compared to the three-month period ended March 31, 2024 ("the first quarter of 2024" or "the prior year period"). "We're pleased with the strong start to the year, highlighted by both our

    5/8/25 4:14:54 PM ET
    $PGNY
    Misc Health and Biotechnology Services
    Health Care

    $PGNY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Progyny Inc.

    SC 13G/A - Progyny, Inc. (0001551306) (Subject)

    12/6/24 10:11:35 AM ET
    $PGNY
    Misc Health and Biotechnology Services
    Health Care

    Amendment: SEC Form SC 13G/A filed by Progyny Inc.

    SC 13G/A - Progyny, Inc. (0001551306) (Subject)

    11/14/24 4:31:23 PM ET
    $PGNY
    Misc Health and Biotechnology Services
    Health Care

    SEC Form SC 13G/A filed by Progyny Inc. (Amendment)

    SC 13G/A - Progyny, Inc. (0001551306) (Subject)

    2/14/24 6:29:49 AM ET
    $PGNY
    Misc Health and Biotechnology Services
    Health Care